PPD signs exclusive agreement with China-based AI company

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/yorkfoto)
(Image: Getty/yorkfoto)

Related tags: China, AI, technological, Patient recruitment, RWE, RWD, Clinical research

PPD’s agreement with China-based Happy Life Tech focuses on site selection, patient recruitment, and real-world evidence generation for customers globally.

The agreement, announced yesterday, brings together HLT’s data and artificial intelligence (AI) technology with PPD’s clinical trials and real-world evidence (RWE) generation abilities.

“The collaboration with HLT provides a creative opportunity to encourage more pharma companies to come to China where we can help them create better optimized protocols that will prove more attractive to sites and investigators because they are tailored more to their patient population,”​ said Niklas Morton, senior vice president of site and patient access for PPD.

As part of the agreement, the contract research organization (CRO) will tap HLT’s network of more than 100 hospitals across 22 Chinese provinces.

Morton explained, “In China, HLT can leverage its large network of physicians and leading Chinese hospitals and has the most advanced analytical capabilities to assist with our strategy of identifying patients first.”

PPD last year launched​ a site solution for enrolling patients in clinical studies, proposing to enroll patients first – before activating sites – via a new enrollment model.

“Traditional clinical research has focused on using site-performance data to identify the strongest sites and investigators for new clinical trials,”​ Morton told us.

“PPD’s recent strategic focus has been on using data to first identify eligible patient populations and then seek the sites and investigators best positioned to access those patients.”

Morton also noted the company’s investment in data over the past five years, citing the agreement as fitting with PPD’s strategy to speed patient enrollment.

“Since we have an exclusive CRO collaboration with HLT that will give us a unique offering for our customers,”​ he added.

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us


View more